Tag: Health Care

Displaying 541 - 560 of 993 results.

Pages

The Commission challenged the conduct of Boulder Valley Individual Practice Association for refusing to deal, or threatening to refuse to deal with insurance providers that failed to increase fees paid to group doctors, and also prevented members from contracting with payers, except...
Physician groups in Modesto, California, and in Boulder County, Colorado, have agreed to settle separate Federal Trade Commission charges that they each violated federal laws. Both groups are charged with orchestrating and carrying out agreements among their members to refuse, and threaten to...
The Commission challenged the conduct of AllCare IPA, alleging that AllCare restrained competition in fee-for-service contracts by fixing prices and other contract terms with payers, engaging in collective negotiations over the terms and conditions of dealing with payers, and...
In order to restore competition in the U.S. market for consumer pregnancy tests, the Commission effectively reversed a consummated transaction in which Inverness Medical Innovations, a 70% market share holder, purchased the assets related to the development of a water-soluble dye...
Teva Pharmaceuticals Industries Ltd.’s has settled Federal Trade Commission charges that its proposed $8.9 billion acquisition of rival generic drugmaker Barr Pharmaceuticals Inc. would be anticompetitive and violate federal law. The consent order requires Teva and Barr to sell assets in 29 U.S....
In 2006, Ovation Pharmaceuticals, manufacturer of Indocin, a drug used in the treatment of patent ductus arteriosus, a congenital heart defect usually found in severely underweight premature babies, purchased the rights to the drug NeoProfen, a drug about to receive FDA approval for...
The Federal Trade Commission today filed a complaint in federal district court challenging Ovation Pharmaceuticals, Inc.’s January 2006 acquisition of the drug NeoProfen, which eliminated its only competitor for the treatment of a serious and potentially deadly congenital heart defect affecting...
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologic Drugs: Framework for Competition and Continued Innovation.” The roundtable will be held in Room 432 at FTC Headquarters in Washington, DC, on November 21, 2008. FTC Commissioner Pamela...
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications...
Following a public comment period, the Commission has approved a final consent order in the matter concerning Fresenius Medical Care AG & Co. KGaA/Daiichi Sankyo Company, Ltd. The vote approving the final order was 4-0. (FTC File No. 081-0146; the staff contact is Elizabeth A. Jex, Bureau of...
Commission approval of public comment period extension – The Commission has approved the publication of a Federal Register notice extending the pubic comment period related to the current regulatory review of the Used Motor Vehicle Trade Regulation Rule (Used Car Rule) through November 19, 2008....
The Federal Trade Commission today announced a complaint challenging Fresenius Medical Care Ag & Co. KGaA’s (Fresenius) proposed acquisition of an exclusive sublicense from Luitpold Pharmaceuticals, Inc. (Luitpold), a wholly owned U.S. subsidiary of the Japanese firm Daiichi Sankyo Company,...
The Commission challenged Fresenius Medical Care’s proposed purchase of an exclusive sublicense for the manufacture and supply of the drug Venofer to US dialysis clinics from Daiichi Sankyo Company. Venofer is an intravenously administered iron sucrose preparation used primarily to...
The Federal Trade Commission today announced that it will hold two public workshops and roundtables this fall to examine emerging health care competition and consumer protection issues. The events, which will be held in Washington, DC, will focus on two distinct areas in which competition and...
The Federal Trade Commission today announced its challenge of Sun Pharmaceutical Industries Ltd.’s (Sun) acquisition of Taro Pharmaceutical Industries Ltd. (Taro), alleging that the transaction as proposed would be anticompetitive and would cause U.S. consumers to pay higher prices for three...
Commission approval of order dismissing administrative complaint – The Commission has approved an order dismissing its administrative complaint against Inova Health System Foundation (Inova) and Prince William Health System, Inc. (PWHS) without prejudice, as the respondents publicly announced...
After a thorough investigation, the FTC filed a complaint in the U.S. District Court for the Eastern District of Virginia on May 12, 2008, seeking an injunction to stop the proposed combination of Inova and Prince William hospitals. The complaint alleges that the transaction would be...
Commission approval of filing of staff comments – The Commission has approved the filing of comments by the staff of the Office of Policy Planning and the Bureaus of Economics, Competition, and Consumer Protection with State Representative Elaine Nekritz, of the Illinois House of Representatives,...
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the agency in fiscal year 2007 (ending September 30, 2007) by generic and branded drug manufacturers.
In a unanimous opinion issued on May 14, the U.S. Court of Appeals for the Fifth Circuit affirmed a 2005 Federal Trade Commission decision that found certain activities of North Texas Specialty Physicians (NTSP) violated Section 5 of the FTC Act. In particular, NTSP, a group of independent...

Pages